Italia markets close in 7 hours 41 minutes

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
20,77+0,89 (+4,48%)
Alla chiusura: 04:00PM EDT
20,86 +0,09 (+0,46%)
Dopo ore: 05:34PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente19,88
Aperto20,05
Denaro20,76 x 600
Lettera20,83 x 600
Min-Max giorno19,85 - 20,92
Intervallo di 52 settimane15,45 - 33,31
Volume801.624
Media Volume1.189.916
Capitalizzazione2,89B
Beta (5 anni mensile)1,33
Rapporto PE (ttm)N/D
EPS (ttm)-1,06
Prossima data utili06 mag 2024 - 10 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A43,56
  • GlobeNewswire

    Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

    Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkersAdditional safety data up to two years of treatment continue to demonstrate that DNL310 is generally well toleratedPreviously reported data showed robust and statistically significant reduction of NfL, a marker of neuronal damage, and positive clinical outcome changes in adaptive behavior,

  • GlobeNewswire

    Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2023, and provided business highlights. “In the second quarter, we shared exciting new data demonstrating robust red

  • GlobeNewswire

    Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

    Interim results demonstrate average reduction of 64% (p <0.001) from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 studyFDA has recommended assessment of NfL, a marker of neuroaxonal damage, as a possible biomarker in MPS IIAdditional interim data from the DNL310 Phase 1/2 study will be presented at the SSIEM symposium in AugustManagement will host a webinar for analysts and investors at 8:30 a.m. Eastern Time today SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSW